Author of

• 11543

  +

  P2.06 - Poster Session 2 - Prognostic and Predictive Biomarkers (ID 165)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Biology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11582

    +

    P2.06-039 - The Status of Epidermal Growth Factor Rceptor (EGFR) Mutation, Protein Overexpression and Gene Amplification in Esophageal Squamous Cell Carcinomas (ID 2848)

    09:30 - 09:30  |  Author(s): G. Zhang
    • Abstract

    Background
    Epidermal growth factor receptor (EGFR) is widely distributed in human epithelial cell membrane, including esophageal squamous cell carcinoma (ESCC). The purpose of this study was to evaluate the relationship between malignant biological behavior and EGFR status in ESCC.

    Methods
    We investigated tumor specimens from 56 patients with surgically resected ESCC from 2004 through 2008. Immunohistochemistry (IHC) was performed to analyze the expression of EGFR. Fluorescence in situ hybridization (FISH) was performed to assess the EGFR gene amplification. EGFR mutations in exons 19-21 were detected by pyrosequencing technology. A chi-square test or Fisher exact test for independence was used to examine the correlation among the status of EGFR protein, gene and the several clinicopathological factors. Overall survival and disease-free survival were constructed using the Kaplan-Meier method, and the log-rank test was used to evaluate the statistical significance of differences. Multivariate analysis was performed using the Cox proportional hazard method.

    Results
    EGFR was overexpressed in 30 of 56 ESCC (53.6%) and was correlated with tumor differentiation (p=0.047) (Figure 1.). EGFR gene amplification was found in 13(23.2%) cases and was correlated with the presence of lymph node metastasis (p=0.001) and higher pathological tumor-node-metastasis (pTNM) stage (p=0.042). There was no EGFR mutation in the clinical samples of 56 patients with ESCC. In univariate analysis, there was no correlation between the prognosis and EGFR protein expression, but EGFR gene amplification was a significant predictor of better prognosis (p=0.031). The multivariate analysis revealed that EGFR gene amplification was significantly correlated with better disease-free survival (p=0.037) and overall survival (OS) (p=0.026). However, patients with EGFR gene amplification did more likely receive aggressive treatment in clinical practice.Figure 1

    Conclusion
    EGFR protein overexpression and gene amplification in ESCC were correlated with the malignant biological behavior, including tumor differentiation and lymph node metastasis. Further studies should be conducted to analyze the prognostic value of EGFR protein overexpression and gene amplification in patients with ESCC.